Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL8670758 | 1.00 | SLC34A1 (0.73) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL29254617 | 1.00 | SLC34A1 (0.73) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL347263 | 1.00 | SLC34A1 (0.73) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL1172442 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL8113536 | 0.95 | SLC34A1 (0.82) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL1259461 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL11166287 | 0.95 | SLC34A1 (0.82) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL9254108 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL20537386 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL16822371 | 0.95 | SLC34A1 (0.67) | SLC34A1LMNAKDM4ECYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4205723-A1 | HIGH TRANSPARENCY, SULPHATE-CONTAINING OR PHOSPHATE-CONTAINING DENTAL SELF-ADHERING COMPOSITE | Ivoclar Vivadent AG (LI) | 2023-07-05 | — | — | EP | claimed |
| CN-114208992-A | Method for improving storage stability of konjac flour | 湖北一致魔芋生物科技股份有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-113520937-A | Cosmetic composition for improving water permeation efficiency | 上海化工研究院有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-109750075-B | Method for converting rare ginsenoside | 山东省分析测试中心 | 2020-12-01 | — | — | CN | claimed |
| CN-111220761-A | High performance liquid chromatography analysis method for determining imidazole content in alkaline reaction solution | 宁夏倬昱新材料科技有限公司 | 2020-06-02 | — | — | CN | claimed |
| CN-107417718-B | The preparation method of everolimus intermediate | 常州兰陵制药有限公司 | 2019-11-15 | — | — | CN | claimed |
| CN-110018254-A | A kind of quality determining method of metho kahuangmin oral administration solution | 江西和盈药业有限公司 | 2019-07-16 | — | — | CN | claimed |
| CN-109828070-A | A kind of measuring method of Chinese medicine Shengxian Tang finger-print | 合肥创新医药技术有限公司 | 2019-05-31 | — | — | CN | claimed |
| CN-109750075-A | A kind of method for transformation of rare ginsenoside | 山东省分析测试中心 | 2019-05-14 | — | — | CN | claimed |
| CN-109470796-A | The detection method of dicarboxylic acids content in a kind of aluminum electrolytic capacitor electrolyte | 江苏国泰超威新材料有限公司 | 2019-03-15 | — | — | CN | claimed |
| CN-1732185-A | Method for crystallizing human serum albumin | TAURUS HSA LLC (US) | 2006-02-08 | — | — | CN | claimed |
| US-6979676-B2 | Pharmaceutical composition containing and indolopyrrolocarbazole derivative | MERCK & CO., INC. (US) | 2005-12-27 | — | — | US | claimed |
| US-20040029821-A1 | Pharmaceutical composition containing an indolopyrrolocarbazole derivative | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2004-02-12 | — | — | US | claimed |
| US-5843924-A | Intravenous alendronate formulations | MERCK & CO., INC. (US) | 1998-12-01 | — | — | US | claimed |
| EP-0472500-B1 | Stabilized chlorodeoxysugar sweetening agents in solid form and methods for preparing same | MCNEIL PPC INC (US) | 1998-11-25 | — | — | EP | claimed |
| EP-0777484-A4 | INTRAVENOUS ALENDRONATE FORMULATIONS | MERCK & CO INC (US) | 1998-08-05 | — | — | EP | claimed |
| EP-0777484-A1 | INTRAVENOUS ALENDRONATE FORMULATIONS | MERCK & CO. INC. (US) | 1997-06-11 | — | — | EP | claimed |
| WO-1996005842-A1 | INTRAVENOUS ALENDRONATE FORMULATIONS | MERCK & CO., INC. (US) | 1996-02-29 | — | — | WO | claimed |
| EP-0472500-A1 | Stabilized chlorodeoxysugar sweetening agents in solid form and methods for preparing same | WARNER-LAMBERT COMPANY (US) | 1992-02-26 | — | — | EP | claimed |
| US-4024031-A | Silver plating | AMP INCORPORATED (US) | 1977-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029821-A1 | Pharmaceutical composition containing an indolopyrrolocarbazole derivative | CYP3A5, CYP2C19, CYP3A7 | SLC34A1 783/4885LMNA 3906/4885KDM4E 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.